Stories
Slash Boxes
Comments

SoylentNews is people

posted by Fnord666 on Friday June 11 2021, @08:33AM   Printer-friendly
from the I-quit! dept.

Member of FDA’s expert panel resigns over Alzheimer’s therapy approval:

Following the Food and Drug Administration's polarizing authorization of the Alzheimer's therapy Aduhelm on Monday, a member of an agency advisory committee that recommended against the drug's approval has resigned.

Neurologist Joel Perlmutter of Washington University in St. Louis, a member of the FDA's expert panel for nervous system therapies, told STAT in an email that he had quit the committee on Monday "due to this ruling by the FDA without further discussion with our advisory committee."

The advisory committee, which convened in November, couldn't have been more openly skeptical of the drug, also known as aducanumab. Ten of the 11 panelists found that there was not enough evidence to show it could slow cognitive decline. The 11th voted "uncertain."


Original Submission

 
This discussion has been archived. No new comments can be posted.
Display Options Threshold/Breakthrough Mark All as Read Mark All as Unread
The Fine Print: The following comments are owned by whoever posted them. We are not responsible for them in any way.
  • (Score: 2) by VLM on Friday June 11 2021, @07:09PM

    by VLM (445) Subscriber Badge on Friday June 11 2021, @07:09PM (#1144349)

    That science stuff doesn't matter any more. The problem is you set up a revolving door system where corporate execs take turns pretending to regulate the industry.

    Normally something like this should have been proposed by a major like Pfizer as one of their many blockbuster billion dollar drugs, but instead a relatively small company is offering it for only $50K/yr per victim of taxpayer medicare money.

    Essentially the wrong people are making money so the insider kingmaker types are PISSED off.

    Now if the regulators were made up of people trying to have a career at Biogen then the regulators would be happy to approve this billion dollar blockbuster. But instead they're Pfizer (and other) career minded people so they're pissed.

    In the end it'll be something like pfizer buys biogen for $20B instead of $10B and the price of the drug will be boosted up another $10K/yr per victim to pay for all the financial foolishness. Kinda like how endless mergers in the phone company arena changed the industry from $5 for a legacy POTS line to $50.

    Starting Score:    1  point
    Karma-Bonus Modifier   +1  

    Total Score:   2